EACVI/HFACardiacOncologyToxicityRegistry in breast cancer patients: Rationale, study design, and methodology (EACVI/HFACOT Registry) - EURObservational Research Program of the European Society of Cardiology

European Heart Journal Cardiovascular Imaging

Volumn 16, Issue 5, 2015, Pages 466-470

  Lancellotti, Patrizio ^a,b   Anker, Stefan D ^c   Donal, Erwan ^d   Edvardsen, Thor ^e,f   Popescu, Bogdan A ^g   Farmakis, Dimitrios ^h   Filippatos, Gerasimos ^h   Habib, Gilbert ^i,j   Maggioni, Aldo P ^k,l   Jerusalem, Guy ^a   Galderisi, Maurizio ^m  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GVM Care and Research ES Health Science Foundation   (Italy)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d UNIVERSITÉ DE RENNES 1   (France)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Centre of Cardiological Innovation   (Norway)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁱ AIX MARSEILLE UNIVERSITY   (France)

^j TIMONE HOSPITAL   (France)

^k ANMCO Study Center   (Italy)

^l EORP Team European Society of Cardiology   (France)

^m FEDERICO II UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Biomarkers; Breast cancer; Cardiac toxicity; Chemotherapy; Left ventricular function

Indexed keywords

ANTINEOPLASTIC AGENT; CARDIOTOXIN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVOR; CARDIOTOXICITY; FOLLOW UP; HEART FAILURE; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG INTERACTION; EUROPE; FEMALE; METHODOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; REGISTER; RISK FACTOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXICITY; CARDIOTOXINS; DRUG INTERACTIONS; EUROPE; FEMALE; HUMANS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGISTRIES; RESEARCH DESIGN; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 84939196014     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jev024     Document Type: Review

References (36)

1. Todaro MC, Oreto L, Qamar R, Paterick TE, Carerj S, Khandheria BK. Cardioncology: state of the heart. Int J Cardiol 2013;168:680-7.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
4. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, DowsettMet al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
5. Verdecchia A, Francisci A, Brenner H, Gatta G, Micheli A, Mangone L et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-96.
6. Bowles EJ,Wellman R, FeigelsonHS, Onitilo AA, FreedmanAN, DelateTet al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104:1293-305.
7. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952-60.
8. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41.
9. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-CrosbieMet al. Expert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15: 1063-93.
10. Brower V. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer. J Natl Cancer Inst 2013;105:835-6.
11. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010;53:105-13.
12. Von Hoff DD, LayardMW, Basa P, DavisHLJr, Von Hoff AL, RozencweigMet al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91: 710-7.
13. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
14. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013;14:721-40.
15. Aapro M, Bernard-Marty C, Brain EG, Batist G, Erdkamp F, Krzemieniecki K et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011;22:257-67.
16. El Zarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 2013;8:e79543.
17. Chien KR. Herceptin and the heart - A molecular modifier of cardiac failure. N Engl J Med 2006;354:789-90.
18. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
19. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-33.
20. Slamon D, EiermannW, Robert N, Pienkowski T, Martin M, Press M et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
21. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CEJr, Ewer MS et al. Seven-year follow-up assessment of cardiac functioninNSABPB-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792-9.
22. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493-8.
23. Yoon GJ, Telli ML, Kao DP, Matsuda KY, CarlsonRW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.
24. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014;15:324-31.
25. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-6.
26. Subar M, Lin W, Chen W, Pittman DG. Lack of uniformity in cardiac assessment during trastuzumab therapy. Breast J 2011;17:383-90.
27. Civelli M, Cardinale D, Martinoni A, Lamantia G, Colombo N, ColomboAet al. Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. Int J Cardiol 2006;111: 120-6.
28. Fallah-Rad N,Walker JR,Wassef A, Lytwyn M, Bohonis S, Fang T et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.
29. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5:596-603.
30. Colombo A, Cardinale D. Using cardiac biomarkers and treating cardiotoxicity in cancer. Future Cardiol 2013;9:105-18.
31. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, BöhmM, DicksteinKet al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
32. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013;6:420-6.
33. Oliva S, Cioffi G, Frattini S, Simoncini EL, Faggiano P, Boccardi L et al.. Administration of angiotensin-converting enzyme inhibitors and betablockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist 2012;17:917-24.
34. Bosch X, Rovira M, Sitges M, Doménech A, Ortiz-Piérez JT, de Caralt TM et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013;61:2355-62.
35. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012;60: 2384-90.
36. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis and management. J Am Coll Cardiol 2009;53:2231-47.